Adagene Announces FDA Clearance of IND for Phase 1b/2 Trial of Anti-CTLA-4 Monoclonal Antibody ADG116 in Combination Therapy with Anti-PD-1 Antibody Pembrolizumab
ADG116-P001 trial being initiated at multiple sites with dosing to begin early 2022SAN DIEGO and SUZHOU, China, Nov. 29, 2021…